The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 31.23%.However, over the last six months, we can see a weaker performance of 120.18%. Over the last 30 days, the price of SLNO has fallen by 23.41%. And in the last five days, it has surged by 40.70%.
Soleno Therapeutics Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $53.82 on 02/28/24 and the lowest value was $3.16 on 05/01/23.
52-week price history of SLNO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Soleno Therapeutics Inc’s current trading price is -1.86% away from its 52-week high, while its distance from the 52-week low is 1571.52%. The stock’s price range during this period has varied between$3.16 and $53.82. The Soleno Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.67 million for the day, a figure considerably higher than their average daily volume of 0.31 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Soleno Therapeutics Inc (SLNO) has experienced a quarterly rise of 10.06% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.76B and boasts a workforce of 42 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 42.70, with a change in price of +23.99. Similarly, Soleno Therapeutics Inc recorded 345,924 in trading volume during the last 100 days, posting a change of +82.90%.
SLNO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for SLNO stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
SLNO Stock Stochastic Average
Soleno Therapeutics Inc’s raw stochastic average for the past 50 days is presently 94.83%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 94.94%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 41.47% and 31.50%, respectively.
